Inventor
NAXIN TU
Inventor
US
Overview
Patents· 11 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A01Kprimary
A01KAnimal husbandry30%
C07KPeptides30%
C12NMicroorganisms or enzymes22%
A61KPreparations for medical, dental or toiletry purposes5%
C07HSugars3%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
C12YEnzymes3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
Y02ATechnologies for adaptation to climate change3%
PatentTitleYear
12,582,105Genetically modified T cell receptor mice202612,433,264Non-human animals having an engineered immunoglobulin lambda light chain locus202512,376,573Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire202512,295,354Non-human animals expressing exogenous terminal deoxynucleotidyltransferase202512,063,915Humanized T cell co-receptor mice202412,036,288Methods of using humanized FCgR mice to assay Fc regions202411,576,984Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using202311,528,895Genetically modified T cell receptor mice202211,503,812Non-human animals having humanized Fc-gamma receptors202211,219,195Genetically modified major histocompatibility complex mice202211,186,848Non-human animals expressing humanized C1Q complex2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to REGENERON PHARMA (11)· patent assignee history
2021–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 11 | 2021–2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 11 | 2021–2026 |